PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v8i5.6924ArticleExploring Novel Therapeutic Breakthroughs for Cancers: Potential Roles of miRNAshttps://artdesignp.com/journal/PAR/8/5/10.26689/par.v8i5.6924AbubakarMuhammad,AyyoubRooma,RehmanBaqaur,KianiMuhammad Naeem,AhmedUsama,FarooqJawaria,UsmaniAreeb Anwar2024852024-09-25MicroRNAs (miRNAs) are small non-coding RNAs, 19–25 nucleotides in length, that regulate gene expression. miRNAs are involved in various cellular, biological, and pathological activities, including the development and progression of malignant tumors. Numerous studies have highlighted the significant roles of miRNA deregulation in various cancer types, involving critical pathways such as gene deletions and amplifications, abnormal epigenetic changes, and dysfunctional miRNA regulatory systems. miRNAs can function both as oncogenes and tumor suppressor genes in different contexts. Several cancer hallmarks are associated with deregulated miRNAs, including resistance to cell death, metastasis, sustained proliferative signaling, promotion of angiogenesis, and the suppression of growth factors. Recent research has demonstrated that miRNAs contribute to drug resistance in tumor cells by targeting genes linked to drug resistance or by influencing genes that regulate the cell cycle, apoptosis, and proliferation. A single miRNA often has tissue-specific regulatory functions and can affect multiple genes. Various miRNA types have been identified as potential biomarkers for tumor diagnosis and critical targets for novel therapeutic approaches. This review aims to explore the role of miRNAs in cancer progression, metastasis, and potential therapeutic interventions.

Ngwa W, Nguyen P, 2017, Global Oncology Outreach: Cancer Prevention and Advocacy, in Global Oncology: Harvard Global Health Catalyst Summit Lecture Notes. IOP Publishing, Bristol, 5-1–5-41.

Otmani K, Lewalle P, 2021, Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications. Front Oncol, 11: 708765. https://doi.org/10.3389/fonc.2021.708765

Lambert M, Benmoussa A, Provost P, 2019, Small Non-Coding RNAs Derived from Eukaryotic Ribosomal RNA. Non-Coding RNA, 5(1): 16. https://doi.org/10.3390/ncrna5010016

He C, Li Z, Chen P, et al., 2012, Young Intragenic miRNAs are Less Coexpressed with Host Genes Than Old Ones: Implications of miRNA-Host Gene Coevolution. Nucleic Acids Res, 40(9): 4002–4012. https://doi.org/10.1093/nar/gkr1312

Yang F, Ning Z, Ma L, et al., 2017, Exosomal miRNAs and miRNA Dysregulation in Cancer-Associated Fibroblasts. Mol Cancer, 16: 148. https://doi.org/10.1186/s12943-017-0718-4

Svoronos AA, Engelman DM, Slack FJ, 2016, OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res, 76(13): 3666–3670. https://doi.org/10.1158/0008-5472.CAN-16-0359

Babashah S, Soleimani M, 2011, The Oncogenic and Tumour Suppressive Roles of MicroRNAs in Cancer and Apoptosis. European Journal of Cancer, 47(8): 1127–1137.

Wang X, Cao L, Wang Y, et al., 2012, Regulation of let-7 and Its Target Oncogenes. Oncology Letters, 3(5): 955–960. https://doi.org/10.3892/ol.2012.609

Abubakar M, Khatoon N, Saddique A, et al., 2024, Skin Cancer and Human Papillomavirus. Journal of Population Therapeutics and Clinical Pharmacology, 31(2): 790–816.

Labi V, Schoeler K, Melamed D, 2019, miR-17~92 in Lymphocyte Development and Lymphomagenesis. Cancer Lett, 446: 73–80. https://doi.org/10.1016/j.canlet.2018.12.020

Bai X, Hua S, Zhang J, Xu S, 2019, The MicroRNA Family Both in Normal Development and in Different Diseases: The miR-17-92 Cluster. BioMed Research International, 2019(1): 9450240. https://doi.org/10.1155/2019/9450240

Li J, Huang H, Sun L, et al., 2009, MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor. Clin Cancer Res, 15(12): 3998–4008. https://doi.org/10.1158/1078-0432.CCR-08-3053

Huang PS, Liao CJ, Huang YH, et al., 2021, Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. Cancers, 13(21): 5361. https://doi.org/10.3390/cancers13215361

Yilmaz M, Kuru RD, Erdogan I, et al., 2022, Investigation of 13q14.3 Deletion By Cytogenetic Analysis and FISH Technique and miRNA-15a and miRNA-16-1 By Real Time PCR in Chronic Lymphocytic Leukemia. African Health Sciences, 22(3): 173–182.

Jiang NJ, Yin YN, Lin J, et al., 2023, MicroRNA-21 in Gynecological Cancers: From Molecular Pathogenesis to Clinical Significance. Pathology – Research and Practice, 248: 154630. https://doi.org/10.1016/j.prp.2023.154630

Guo X, Li Y, Che X, et al., 2022, microRNA-569 Inhibits Tumor Metastasis in Pancreatic Cancer by Directly Targeting NUSAP1. Aging (Albany NY), 14(8): 3652–3665. https://doi.org/10.18632/aging.204035

Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, et al., 2023, Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA. Int J Mol Sci, 24(8): 7235. https://doi.org/10.3390/ijms24087235

Arif KMT, Elliot EK, Haupt LM, et al., 2020, Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets. Cancers, 12(10): 2922. https://doi.org/10.3390/cancers12102922

Chen J, Zhao KN, 2015, HPV-p53-miR-34a axis in HPV-Associated Cancers. Annals of Translational Medicine, 3(21): 331. https://doi.org/10.3978/j.issn.2305-5839.2015.09.39

Si W, Shen J, Zheng H, et al., 2019, The Role and Mechanisms of Action of microRNAs in Cancer Drug Resistance. Clin Epigenet, 11: 25. https://doi.org/10.1186/s13148-018-0587-8

Song MS, Salmena L, Pandolfi PP, 2012, The Functions and Regulation of the PTEN Tumour Suppressor. Nat Rev Mol Cell Biol, 13(5): 283–296. https://doi.org/10.1038/nrm3330

Ala U, 2020, Competing Endogenous RNAs, Non-Coding RNAs and Diseases: An Intertwined Story. Cells, 9(7): 1574. https://doi.org/10.3390/cells9071574

Thivierge C, Tseng HW, Mayya VK, et al., 2018, Alternative Polyadenylation Confers Pten mRNAs Stability and Resistance to microRNAs. Nucleic Acids Res, 46(19): 10340–10352. https://doi.org/10.1093/nar/gky666

Szabo Z, Szegedi K, Gombos K, et al., 2016, Expression of miRNA-21 and miRNA-221 in Clear Cell Renal Cell Carcinoma (ccRCC) and Their Possible Role in the Development of ccRCC. Urol Oncol Semin Orig Investig, 34: 533.e21–533.e27. https://doi.org/10.1016/j.urolonc.2016.06.011

Zhou XJ, Wu J, Shi L, et al., 2017, PTEN Expression is Upregulated by a RNA-Binding Protein RBM38 via Enhancing Its mRNA Stability in Breast Cancer. J Exp Clin Cancer Res, 36(1): 149. https://doi.org/10.1186/s13046-017-0620-3

Tyagi N, Arora S, Deshmukh SK, et al., 2016, Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics. Journal of Biomedical Nanotechnology, 12(1): 28–42. https://doi.org/10.1166/jbn.2016.2172

He L, Thomson JM, Hemann MT, et al., 2005, A MicroRNA Polycistron as A Potential Human Oncogene. Nature, 435(7043): 828–833. https://doi.org/10.1038/nature03552

Esquela-Kerscher A, Slack FJ, 2006, Oncomirs – MicroRNAs with A Role in Cancer. Nat Rev Cancer, 6(4): 259–269. https://doi.org/10.1038/nrc1840

He XY, Chen JX, Zhang Z, et al., 2010, The let-7a MicroRNA Protects From Growth of Lung Carcinoma by Suppression of k-Ras and c-Myc in Nude Mice. J Cancer Res Clin Oncol, 136(7): 1023–1028. https://doi.org/10.1007/s00432-009-0747-5

Okada N, Lin CP, Ribeiro MC, et al., 2014, A Positive Feedback Between p53 and miR-34 miRNAs Mediates Tumor Suppression. Genes Dev, 28(5): 438–450. https://doi.org/10.1101/gad.233585.113

Li Y, Sun Z, Liu B, et al., 2017, Tumor-Suppressive miR-26a and miR-26b Inhibit Cell Aggressiveness by Regulating FUT4 in Colorectal Cancer. Cell Death Dis, 8(6): e2892. https://doi.org/10.1038/cddis.2017.281

Lima JF, Cerqueira L, Figueiredo C, et al., 2018, Anti-miRNA Oligonucleotides: A Comprehensive Guide for Design. RNA Biol, 15(3): 338–352. https://doi.org/10.1080/15476286.2018.1445959

Tang L, Chen HY, Hao NB, et al., 2017, microRNA Inhibitors: Natural and Artificial Sequestration of MicroRNA. Cancer Lett, 407: 139–147. https://doi.org/10.1016/j.canlet.2017.05.025

Samad AFA, Kamaroddin MF, 2023, Innovative Approaches in Transforming MicroRNAs into Therapeutic Tools. Wiley Interdiscip Rev RNA, 14(1): e1768. https://doi.org/10.1002/wrna.1768

Inui M, Martello G, Piccolo S, 2010, MicroRNA Control of Signal Transduction. Nat Rev Mol Cell Biol, 11(4): 252–263. https://doi.org/10.1038/nrm2868

Salarinia R, Sahebkar A, Peyvandi M, et al., 2016, Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies. Curr Cancer Drug Targets, 16(9): 773–788. https://doi.org/10.2174/1568009616666151207110143

Pelaz B, Alexiou C, Alvarez-Puebla RA, et al., 2017, Diverse Applications of Nanomedicine. ACS Nano, 11(3): 2313–2381. https://doi.org/10.1021/acsnano.6b06040

Militello G, Weirick T, John D, et al., 2017, Screening and Validation of lncRNAs and circRNAs as miRNA Sponges. Brief Bioinform, 18(5): 780–788. https://doi.org/10.1093/bib/bbw053

Hou Y, Sun J, Huang J, et al., 2021, Circular RNA circRNA_0000094 Sponges microRNA-223-3p and Up-regulate F-box and WD Repeat Domain Containing 7 to Restrain T Cell Acute Lymphoblastic Leukemia Progression. Hum Cell, 34(3): 977–989. https://doi.org/10.1007/s13577-021-00504-4. Erratum in Hum Cell, 34(5): 1584. https://doi.org/10.1007/s13577-021-00574-4

Huang W, Huang T, Liu Y, et al., 2021, Nuclear Factor I-C Disrupts Cellular Homeostasis Between Autophagy and Apoptosis via miR-200b-Ambra1 in Neural Tube Defects. Cell Death Dis, 13(1): 17. https://doi.org/10.1038/s41419-021-04473-2

Forterre A, Komuro H, Aminova S, et al., 2020, A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers, 12(7): 1852. https://doi.org/10.3390/cancers12071852

Rezaei Z, Sadri F, 2021, MicroRNAs Involved in Inflammatory Breast Cancer: Oncogene and Tumor Suppressors with Possible Targets. DNA Cell Biol, 40(3): 499–512. https://doi.org/10.1089/dna.2020.6320

Inoue J, Inazawa J, 2021, Cancer-Associate miRNAs and Their Therapeutic Potential. J Hum Genet, 66: 937–945. https://doi.org/10.1038/s10038-021-00938-6

Yousaf A, Tasneem N, Mustafa A, et al., 2021, Gastric Cancer Associated Risk Factors and Prevalence in Pakistan. ASEAN Journal of Science and Engineering, 1(2): 73–78.

Li XJ, Ren ZJ, Tang JH, 2014, MicroRNA-34a: A Potential Therapeutic Target in Human Cancer. Cell Death Dis, 5(7): e1327. https://doi.org/10.1038/cddis.2014.270

Zhang W, Jiang Y, He Y, et al., 2023, Lipid Carriers for mRNA Delivery. Acta Pharm Sin B, 13(10): 4105–4126. https://doi.org/10.1016/j.apsb.2022.11.026

Gomarasca M, Maroni P, Banfi G, et al., 2020, microRNAs in the Antitumor Immune Respose and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. Int J Mol Sci, 21(8): 2805. https://doi.org/10.3390/ijms21082805

Fernandes M, Marques H, Teixeira AL, et al., 2021, miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin’s Lymphoma: Moving Towards an RNA-Guided Precision Medicine. Cancers, 13(24): 6324. https://doi.org/10.3390/cancers13246324

Conde J, Arnold CE, Tian F, et al., 2016, RNAi Nanomaterials Targeting Immune Cells as An Anti-Tumor Therapy: The Missing Link in Cancer Treatment? Materials Today, 19(1): 29–43. https://doi.org/10.1016/j.mattod.2015.07.005

Tang L, Mei Y, Shen Y, et al., 2021, Nanoparticle-Mediated Targeted Drug Delivery to Remodel Tumor Microenvironment for Cancer Therapy. Int J Nanomedicine, 16: 5811–5829. https://doi.org/10.2147/IJN.S321416

Krichevsky AM, Uhlmann EJ, 2019, Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Neurotherapeutics, 16(2): 319–347. https://doi.org/10.1007/s13311-018-00702-3

Honda T, Yamamoto Y, Daito T, et al., 2016, Long-Term Expression of miRNA for RNA Interference Using A Novel Vector System Based on A Negative-Strand RNA Virus. Sci Rep, 6: 26154. https://doi.org/10.1038/srep26154

Kasar S, Underbayev C, Hassan M, et al., 2016, Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL). PLoS One, 11(3): e0149331. https://doi.org/10.1371/journal.pone.0149331

Yuan Y, Kasar S, Underbayev C, et al., 2012, MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders. Leuk Res Treatment, 2012: 603830. https://doi.org/10.1155/2012/603830

Furukawa N, Sakurai F, Katayama K, et al., 2011, Optimization of A MicroRNA Expression Vector for Function Analysis of MicroRNA. J Control Release, 150(1): 94–101. https://doi.org/10.1016/j.jconrel.2010.12.001

Sasso E, D'Alise AM, Zambrano N, et al., 2020, New Viral Vectors for Infectious Diseases and Cancer. Semin Immunol, 50: 101430. https://doi.org/10.1016/j.smim.2020.101430

Kiani MN, Butt MS, Gul IH, et al., 2023, Synthesis and Characterization of Cobalt-Doped Ferrites for Biomedical Applications. ACS Omega, 8(4): 3755–3761. https://doi.org/10.1021/acsomega.2c05226

Gu Z, Da Silva CG, Van der Maaden K, et al., 2020, Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics, 12(11): 1054. https://doi.org/10.3390/pharmaceutics12111054

Caruso S, Poon IKH, 2018, Apoptotic Cell-Derived Extracellular Vesicles: More Than Just Debris. Front Immunol, 9: 1486. https://doi.org/10.3389/fimmu.2018.01486

Liu S, Wu X, Chandra S, et al., 2022, Extracellular Vesicles: Emerging Tools as Therapeutic Agent Carriers. Acta Pharm Sin B, 12(10): 3822–3842. https://doi.org/10.1016/j.apsb.2022.05.002

Ohno S, Drummen GP, Kuroda M, 2016, Focus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic Systems. Int J Mol Sci, 17(2): 172. https://doi.org/10.3390/ijms17020172

Fu Y, Chen J, Huang Z, 2019, Recent Progress in MicroRNA-Based Delivery Systems for the Treatment of Human Disease. ExRNA, 1: 24. https://doi.org/10.1186/s41544-019-0024-y

Volpini L, Monaco F, Santarelli L, et al., 2023, Advances in RNA Cancer Therapeutics: New Insight into Exosomes as miRNA Delivery. Aspects of Molecular Medicine, 1: 100005. https://doi.org/10.1016/j.amolm.2023.100005

Cornejo MA, Linz TH, 2023, Selective miRNA Quantitation with High-Temperature Thermal Gel Electrophoresis. Anal Chim Acta, 1275: 341605. https://doi.org/10.1016/j.aca.2023.341605

Ranjbar S, Zhong XB, Manautou J, et al., 2023, A Holistic Analysis of the Intrinsic and Delivery-Mediated Toxicity of siRNA Therapeutics. Adv Drug Deliv Rev, 201: 115052. https://doi.org/10.1016/j.addr.2023.115052